Viewpoints Archives - Page 4 of 11 - Innovation and Value Initiative

Using Outcomes-Based Pricing for Medical Devices to Improve Cardiovascular Disease Treatment Value
Using Outcomes-Based Pricing for Medical Devices to Improve Cardiovascular Disease Treatment Value

Viewpoints

Using Outcomes-Based Pricing for Medical Devices to Improve Cardiovascular Disease Treatment Value

In a post on the IVI-sponsored Health Affairs featured blog series Drugs and Medical Innovation, Daniel Blumenthal, Samuel Nussbaum (IVI Strategic Advisory Panel Chair), Mark Linthicum (IVI Director of Scientific Communications), and Neil Weissman (IVI Strategic Advisory Panel member) explore how outcomes-based pricing agreements (OBAs) could be utilized for medical devices used to treat cardiovascular [...]

Hanh2018-03-30T18:04:16-04:00March 29th, 2018|Viewpoints|

To Get Our Money’s Worth in Healthcare, We Need to Collaborate
To Get Our Money’s Worth in Healthcare, We Need to Collaborate

Viewpoints

To Get Our Money’s Worth in Healthcare, We Need to Collaborate

In a commentary for Modern Healthcare, IVI Director of Scientific Communications, Mark Linthicum, emphasizes that the healthcare system needs to embrace collaboration to find consensus in the way we measure and pay for health care value. Read the full article here.

Hanh2018-01-22T22:29:16-05:00January 22nd, 2018|Viewpoints|

Well-Informed Patients Play a Key Role in Value-Based Care
Well-Informed Patients Play a Key Role in Value-Based Care

Viewpoints

Well-Informed Patients Play a Key Role in Value-Based Care

In a commentary for Morning Consult, Virginia Ladd, President and Executive Director of the American Autoimmune Related Diseases Association (AARDA), emphasizes how critical it is that the patient perspective be front and center in discussions about how we measure and pay for value. Read the full article here.

Hanh2018-01-18T05:19:24-05:00January 12th, 2018|Viewpoints|

Putting More Value Into Biopharmaceutical Value Assessments
Putting More Value Into Biopharmaceutical Value Assessments

Viewpoints

Putting More Value Into Biopharmaceutical Value Assessments

In a commentary for the Health Affairs Blog, Rena M. Conti, PhD, and IVI Executive Director, Darius Lakdawalla, argue that advancing the science of value assessment requires new assessment tools that are transparent and incorporate the perspectives of patients and insurance plan enrollees. Read the full article here.

Hanh2018-02-23T20:39:07-05:00January 4th, 2018|Viewpoints|

An Open-Source Consensus-Based Approach to Value Assessment
An Open-Source Consensus-Based Approach to Value Assessment

Viewpoints

An Open-Source Consensus-Based Approach to Value Assessment

In a commentary for the Health Affairs Blog, IVI's Jeroen Jansen, Devin Incerti, and Mark Linthicum argue that, in order to move toward consensus on value assessment, the process for defining and measuring value must be transparent, collaborative, and iterative. IVI is taking the first steps towards consensus with the development of the Open-Source Value Project. [...]

Hanh2017-12-15T23:12:42-05:00December 15th, 2017|Viewpoints|

IVI’s Mark Linthicum in Morning Consult: Why Understanding Value is Central to True Health Care Reform
IVI’s Mark Linthicum in Morning Consult: Why Understanding Value is Central to True Health Care Reform

Viewpoints

IVI’s Mark Linthicum in Morning Consult: Why Understanding Value is Central to True Health Care Reform

Mark Linthicum makes the case that value-based spending should be the focus of health care reform efforts in Washington, D.C. On September 13th health care stakeholders came together at the National Press Club to discuss better approaches to measuring value. Read Full Article Here

Hanh2017-11-11T01:18:31-05:00September 20th, 2017|Viewpoints|

Shafrin Defines Precision Medicine for U.S. News and World Report
Shafrin Defines Precision Medicine for U.S. News and World Report

Viewpoints

Shafrin Defines Precision Medicine for U.S. News and World Report

In a new commentary for U.S. News and World Report, Jason Shafrin defines and elaborates on the field of precision medicine. Jason, IVI's Director of Research, illustrates how the United States is moving headlong into this new treatment approach. He notes some of the challenges while also emphasizing the unique hope precision medicine brings through [...]

Hanh2017-11-11T01:22:04-05:00August 25th, 2017|Viewpoints|

Sachs Provides an Overview of FDA User Fee Reauthorization Bill
Sachs Provides an Overview of FDA User Fee Reauthorization Bill

Viewpoints

Sachs Provides an Overview of FDA User Fee Reauthorization Bill

In a recent post on the IVI-Sponsored Health Affairs blog series, Rachel Sachs provides an overview of the House of Representative's latest draft of the FDA user fee authorization bill. Sachs also examines changes in the bill from the earlier Senate markup, including incorporation of provisions from the bipartisan RACE Act and provides a possible [...]

Hanh2017-11-09T02:27:26-05:00July 13th, 2017|Viewpoints|

Sachs Summarizes Recent HELP Committee Meeting: The Elephant in the Room
Sachs Summarizes Recent HELP Committee Meeting: The Elephant in the Room

Viewpoints

Sachs Summarizes Recent HELP Committee Meeting: The Elephant in the Room

In the latest post on the the IVI-sponsored Health Affairs blog series, Rachel Sachs summarizes the recent Senate Health, Education, Labor & Pensions (HELP) Committee meeting. Organized to address the drug delivery system and how it influences what patients pay, the meeting quickly shifted to a partisan blasting of the secretive process by which Republicans [...]

Hanh2017-07-14T05:22:13-04:00June 20th, 2017|Viewpoints|

Lietzan Examines SCOTUS Ruling on Biosimilars
Lietzan Examines SCOTUS Ruling on Biosimilars

Viewpoints

Lietzan Examines SCOTUS Ruling on Biosimilars

In the latest post on the the IVI-sponsored Health Affairs blog series, Drugs and Medical Innovation, Erica Lietzan takes a look at the recent Supreme Court ruling on Sandoz v. Amgen, examining premarket patent litigation, patent resolution process, state law influence, and the impact of the SCOTUS ruling itself. Read the full article here.

Hanh2017-07-14T05:22:20-04:00June 19th, 2017|Viewpoints|